Search

Displaying results 5631 - 5640 of 10000 in total
  1. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). … It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.

  2. Drug

    Methoxyamine

    go.drugbank.com/drugs/DB06328
    Investigational

  3. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  4. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Synonyms: L-FMAU, 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracilCategories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  6. Drug

    Skin-derived ABCB5-positive Mesenchymal Stem cells

    go.drugbank.com/drugs/DB17862
    Investigational

    Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).

    Synonyms: allo-APZ2-EB
  7. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  8. Drug

    VV-14300

    go.drugbank.com/drugs/DB33996
    Experimental

    VV-14300 is a biologic drug. VV-14300 is under investigation in clinical trial NCT07829302 (VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes).

  9. Drug

    VV-14299

    go.drugbank.com/drugs/DB33997
    Experimental

    VV-14299 is a biologic drug. VV-14299 is under investigation in clinical trial NCT07829302 (VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes).

  10. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.